Biology

Not all electronic cigarette devices are created equal. Some fourth-generation models—such as Juul devices—are associated with unique changes in markers of immune responses inside our airways, according to a new paper from UNC School of Medicine researchers led by toxicologist Ilona Jaspers, Ph.D., director of the UNC Center for Environmental Medicine, Asthma, and Lung Biology and director of the UNC Curriculum in Toxicology and Environmental Medicine.

PARIS — Symrise Cosmetic Ingredients has partnered with Evoxx, a biotech company, to develop biotechnological processes for beauty ingredients. “Evoxx contributes its expertise in research and development, as well as its global leadership in manufacturing of enzymes and probiotics,” Symrise, the Holzminden, Germany-based fragrance and flavors supplier, said in a statement released Thursday. “Symrise adds their knowledge and capabilities in creating innovative and sustainable cosmetics ingredients.”

Researchers from University Hospital Frankfurt and Goethe University Frankfurt have unraveled how bacteria adhere to host cells and thus taken the first step towards developing a new class of antibiotics. The adhesion of bacteria to host cells is always the first, decisive step in the development of infectious diseases. The...

Let's consider the risk-reward profile of these companies before jumping on the bandwagon.

The shares of commercial-stage biotech Amarin Corporation (NASDAQ:AMRN) dropped sharply on Thursday after Stat News raised concerns over the effectiveness of its heart disease therapy Vascepa. Following a new analysis, the report said that multiple experts.

Clinical-stage biotech Immunome (NASDAQ:IMNM) added ~34% on Thursday after data indicated that the company’s experimental three-antibody cocktail IMM-BCP-01 was effective against COVID-19 variants of concern, including BA.1 and BA.2. IMM-BCP-01 consists of three patient-derived neutralizing antibodies that.

French biotech Onxeo (OTC:OXNXF) on Thursday said the U.S. FDA had cleared its initial investigational new drug (IND) application for its oncology drug AsiDNA. OXNXF can now start a phase 1b/2 trial to evaluate AsiDNA in combination with olaparib (a type.

COVID-related revenue will decrease but won't go away entirely. Moderna has dozens of products in development, including a few in phase 3 trials. Investors shouldn't assume the cheap valuation means an investment is without risk. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More. What happened. Thursday was generally a lousy day...

Biology is messy. For scientists, that’s part of its challenge—and its beauty. Synthetic biologists, however, aren’t just studying life. Instead, the field of synthetic biology is transforming cells into molecular factories that can make everything from food and fuel to pharmaceuticals and agriculture. The natural complexity and stochasticity of living systems makes this a complex task. To reprogram a cell requires more than just the right genes, it requires precisely balancing the timing and expression of each gene so reactions proceed in the right order and at the right time. Doing this requires accurate and precise editing methods and rounds and rounds of tuning.

Heron Therapeutics Inc. HRTX, -12.30% said Thursday it will lay off about one-third of its workforce as part of a restructuring expected to save $43 million a year. The biotechnology company's stock was still inactive in premarket trading. The company said it's enacting the restructuring and cost cutting measures to address "the current market realities and macro headwinds facing many commercial-stage biotechnology companies," and to help support its acute care and oncology care franchises. The company said the cost cutting actions will mostly result from the reduction of 34% of its workforce, which would represent about 103 employees, based on 302 full-time employees the company had as of Dec. 31. Heron said about 70% of the jobs being cut are coming from research and development. The stock has plunged 65.3% year to date, while the iShares Biotechnology ETF.